4D Molecular Therapeutics, Inc. 4

Chief Legal Officer Scott Bizily exercised 584 stock options at $6.49 and sold 584 shares of 4D Molecular Therapeutics, Inc. common stock at $14.00 on September 1, 2026 under a 10b5-1 plan.

On September 1, 2026, 4D Molecular Therapeutics, Inc. Chief Legal Officer Scott Bizily exercised 584 stock options at an exercise price of $6.49 per share, acquiring 584 shares of common stock for approximately $3,790, and on the same day sold 584 shares of common stock at $14.00 per share for proceeds of approximately $8,176 under a Rule 10b5-1 trading plan. Following these transactions, which appear to be a routine cashless/cover transaction associated with an existing option grant that vests monthly over four years beginning June 16, 2022, Bizily held 9,201 shares of common stock directly and 2,959 options (or option-derived rights) remaining, with no indication of additional discretionary open-market purchases or sales beyond the option-related sale.

Filing Facts

CIK

1650648

Ticker

FDMT

Form

4

Source Type

fda

Accession

0001193125-26-382245

Alert Tier

5